Consequently, TENM1-targeting could be proposed as a new strategy for glioblastoma therapy, as TENM1 overexpression is induced by hypoxia, and a hypoxic tumor microenvironment is associated with treatment resistance and poor prognosis. The gene discussed is TENM1; the disease is glioblastoma.